Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laserscope gains US nod for BPH (benign prostatic hyperplasia) laser therapy:

This article was originally published in Clinica

Executive Summary

The US FDA has given Laserscope the go-head to market its high-power KTP laser system for the treatment of benign prostatic hyperplasia (BPH). Laserscope claims that three-year follow-up trial data show that the flow rate and American Urology Association symptom score (two major clinical measurements of effectiveness) following KTP therapy are as good as or better than those for any other available BPH therapy, including those published for the current gold standard procedure, transurethral resection of the prostate. The San Jose, California firm plans to begin shipping the product later this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel